Compare BGSF & ATNM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BGSF | ATNM |
|---|---|---|
| Founded | 2007 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Professional Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.1M | 50.2M |
| IPO Year | N/A | N/A |
| Metric | BGSF | ATNM |
|---|---|---|
| Price | $4.46 | $1.45 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $9.00 | $4.00 |
| AVG Volume (30 Days) | 67.9K | ★ 206.2K |
| Earning Date | 11-07-2025 | 11-14-2025 |
| Dividend Yield | ★ 44.44% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $263,687,000.00 | $90,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.14 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 71.60 | 11.11 |
| 52 Week Low | $2.91 | $1.03 |
| 52 Week High | $8.22 | $2.41 |
| Indicator | BGSF | ATNM |
|---|---|---|
| Relative Strength Index (RSI) | 59.36 | 54.26 |
| Support Level | $4.29 | $1.33 |
| Resistance Level | $4.76 | $1.48 |
| Average True Range (ATR) | 0.22 | 0.11 |
| MACD | 0.08 | 0.02 |
| Stochastic Oscillator | 69.57 | 58.90 |
BGSF Inc is a national provider of consulting, managed services, and professional workforce solutions. two segments: Property Management and Professional. In the Property Management segment is a provider of office and maintenance talent. The Professional segment provides IT professionals with expertise in SAP, Workday, Peoplesoft, Hyperion, Oracle, One Stream, cyber, project management, managed services, and other IT workforce solutions to client partners on a national basis. The group generates the majority of its revenue from the Professional segment.
Actinium Pharmaceuticals Inc is a biopharmaceutical company engaged in the development of radiotherapies for patients with cancers lacking effective treatment options. The company's proprietary technology platform utilizes monoclonal antibodies to deliver radioisotopes directly to cells of interest to kill those cells safely and effectively. Its product candidates are Iomab-B, an antibody-drug construct containing iodine 131 (I-131), used for hematopoietic stem cells transplantation in various indications, and Actimab-A, an antibody-drug construct containing actinium 225 (Ac-225), currently in human clinical trials for acute myeloid leukemia.